Published

Scanning the new frontier of mental health: psychedelic brain imaging

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: The Biochemist
Date: 2024-03-14
Source: OpenAlex
DOI: 10.1042/bio_2023_171
PubMed: Unavailable

Authors

Natalie Ertl Matthew B. Wall

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Addiction Brain Imaging Mechanism of Action Receptor Pharmacology Consciousness Aging Emotional Processing Spirituality Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15 Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-28 Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01 Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric DisordersPsychiatry and Clinical Psychopharmacology · 2026-03-30 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’Behavioural Pharmacology · 2026-05-06 Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophreniaNeuropsychopharmacology · 2026-07-18 Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01